Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns CombiMatrix of Failure to Meet Listing Requirement

NEW YORK (GenomeWeb News) – CombiMatrix has been warned by Nasdaq that it doesn't meet a requirement to remain being listed on the exchange, the Irvine, Calif.-based firm said after the close of the market on Friday.

CombiMatrix said that it received a notification dated June 26 from the Listing Qualifications department of Nasdaq telling the company that it was in violation of a listing requirement calling for a minimum bid of $1 per share, "based upon the closing bid price for the last 30 consecutive business days."

CombiMatrix has 180 calendar days to regain compliance. If during that time the firm's stock closes at or above $1 per share for at least 10 consecutive business days, Nasdaq will provide the company with written confirmation of compliance and the matter will be closed.

If the company does not regain compliance during the 180 days, Nasdaq will provide written notification that it is subject to delisting action. CombiMatrix would be able to appeal the delisting determination.

Also, if CombiMatrix fails to regain compliance with the $1 minimum bid rule, but meets other listing requirements — including a minimum market value requirement — and provides written notice that it plans to resolve the minimum bid issue with a reverse stock split, if necessary, it will be given an additional 180 days to regain compliance.

At the close of the market on Friday, shares of CombiMatrix were down 19 percent to $.85.

In late 2010 when CombiMatrix's stock was trading on the Nasdaq Global Market, it was warned that it was in violation of a listing requirement calling for a minimum of $10 million in stock equity. The company transferred to the Nasdaq Capital Market, which has a stock equity listing requirement of $2.5 million, in response.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.